UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2008
MELO BIOTECHNOLOGY HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Canada (State of Incorporation) | 03-30801 (Commission File No.) | N/A (IRS Employer Identification No.) |
| | | |
Room 1411, West Tower, Shuntak Center, 168-200 Connaught Rd., Central, Hong Kong |
(Address of principal executive offices) |
Registrant’s Telephone Number, including area code: 852-2559-8000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
ITEM 5.02 DEPARTURE OF CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERATIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On October 15, 2008, Mr. Michael Medlock resigned from his position as the Chief Executive Officer of Melo Biotechnology Holdings, Inc. (the “Company”). Mr. Medlock’s resignation was not due to a disagreement with the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.
Melo Biotechnology Holdings Inc.
By: /S/ Fung Ming
Fung Ming, Director
October 21, 2008
2
